Checkpoint Capital L.P. is an investment fund managing more than $166 billion ran by Sam Huang. There are currently 16 companies in Mr. Huang’s portfolio. The largest investments include Rhythm Pharmaceuticals and Argenx Se, together worth $73.2 billion.
As of 7th August 2024, Checkpoint Capital L.P.’s top holding is 922,100 shares of Rhythm Pharmaceuticals currently worth over $37.9 billion and making up 22.8% of the portfolio value.
Relative to the number of outstanding shares of Rhythm Pharmaceuticals, Checkpoint Capital L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 82,150 shares of Argenx Se worth $35.3 billion.
The third-largest holding is Axsome Therapeutics Inc worth $23.4 billion and the next is Avadel Pharmaceuticals plc worth $16 billion, with 1,138,178 shares owned.
Currently, Checkpoint Capital L.P.'s portfolio is worth at least $166 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Checkpoint Capital L.P. office and employees reside in San Francisco, California. According to the last 13-F report filed with the SEC, Sam Huang serves as the Managing Member at Checkpoint Capital L.P..
In the most recent 13F filing, Checkpoint Capital L.P. revealed that it had opened a new position in
Avadel Pharmaceuticals plc and bought 1,138,178 shares worth $16 billion.
This means they effectively own approximately 0.1% of the company.
Avadel Pharmaceuticals plc makes up
12.3%
of the fund's Health Care sector allocation and has grown its share price by 16.4% in the past year.
The investment fund also strengthened its position in Rhythm Pharmaceuticals by buying
96,600 additional shares.
This makes their stake in Rhythm Pharmaceuticals total 922,100 shares worth $37.9 billion.
Rhythm Pharmaceuticals soared 73.9% in the past year.
On the other hand, there are companies that Checkpoint Capital L.P. is getting rid of from its portfolio.
Checkpoint Capital L.P. closed its position in Avadel Pharmaceuticals plc on 14th August 2024.
It sold the previously owned 701,387 shares for $11.8 billion.
Sam Huang also disclosed a decreased stake in Corcept Therapeutics Inc by 0.1%.
This leaves the value of the investment at $7.95 billion and 244,750 shares.
The two most similar investment funds to Checkpoint Capital L.P. are Leslie Global Wealth and Aua Capital Management. They manage $166 billion and $166 billion respectively.
Checkpoint Capital L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 78.7% of
the total portfolio value.
The fund focuses on investments in the United States as
87.5% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
31% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $990 million.
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Rhythm Pharmaceuticals Inc. |
11.70%
922,100
|
$37,861,426,000 | 22.82% |
| Argenx Se |
0.18%
82,150
|
$35,327,786,000 | 21.30% |
| Axsome Therapeutics Inc |
119.55%
290,772
|
$23,407,146,000 | 14.11% |
| Avadel Pharmaceuticals plc |
Opened
1,138,178
|
$16,002,783,000 | 9.65% |
| Protagonist Therapeutics Inc |
26.65%
355,000
|
$12,300,750,000 | 7.42% |
| Avadel Pharmaceuticals plc |
Closed
701,387
|
$11,846,426,000 | |
| Cytokinetics Inc |
No change
190,000
|
$10,294,200,000 | 6.21% |
| Mirum Pharmaceuticals Inc |
Closed
362,193
|
$9,098,288,000 | |
| Phathom Pharmaceuticals Inc |
96.56%
875,000
|
$9,012,500,000 | 5.43% |
| Corcept Therapeutics Inc |
10.60%
244,750
|
$7,951,928,000 | 4.79% |
| Ironwood Pharmaceuticals Inc |
Closed
618,528
|
$5,387,379,000 | |
| Atyr Pharma Inc |
34.57%
1,946,477
|
$3,036,504,000 | 1.83% |
| Pliant Therapeutics, Inc. |
Opened
232,200
|
$2,496,150,000 | 1.50% |
| Kymera Therapeutics, Inc. |
Opened
82,000
|
$2,447,700,000 | 1.48% |
| Verastem Inc |
Closed
168,739
|
$1,991,120,000 | |
| Gh Research Plc |
Closed
185,653
|
$1,979,061,000 | |
| Cidara Therapeutics Inc |
Opened
145,417
|
$1,736,279,000 | 1.05% |
| Trevi Therapeutics, Inc. |
1.18%
500,089
|
$1,490,265,000 | 0.90% |
| Applied Therapeutics, Inc. |
3.40%
227,470
|
$1,062,285,000 | 0.64% |
| Soleno Therapeutics Inc |
Opened
19,695
|
$803,556,000 | 0.48% |
| Allakos Inc |
15.37%
649,957
|
$649,957,000 | 0.39% |
| Atara Biotherapeutics Inc |
Closed
892,853
|
$619,640,000 | |
| No transactions found | |||
| Showing first 500 out of 22 holdings | |||